Table 3.

Prognostic impact of PD-L1 upregulation (versus no change or downregulation) following platinum-based NACT

Model	Disease-free survival		Overall survival
	HR (95% CI)	p-value	HR (95% CI)	p-value
Model 1a)	1.17 (0.67-2.03)	0.578	1.69 (0.89-3.22)	0.111
Model 2b)	1.32 (0.73-2.39)	0.366	1.60 (0.80-3.18)	0.182
Model 3c)	0.89 (0.46-1.70)	0.718	1.53 (0.69-3.38)	0.290

PD-L1, programmed death ligand 1; NACT, neoadjuvant chemotherapy; HR, hazard ratio; CI, confidence interval.

^a)Model 1 is adjusted for age (≥ 65 vs. < 65), pretreatment clinical stage (I-II vs. III), and pathologic N category (ypN0 vs. ypN1 vs. ypN2 vs. ypN3),

^b)Model 2 is adjusted for age (≥ 65 vs. < 65), pretreatment clinical stage (I-II vs. III), pathologic N category (ypN0 vs. ypN1 vs. ypN2 vs. ypN3), and pre-NACT PD-L1 tumor proportion score (< 1% vs. 1%-50% vs. ≥ 50%),

^c)Model 3 is adjusted for age (≥ 65 vs. < 65), pretreatment clinical stage (I-II vs. III), pathologic N category (ypN0 vs. ypN1 vs. ypN2 vs. ypN3), and post-NACT PD-L1 tumor proportion score (< 1% vs. 1-50% vs. ≥ 50%).